Detail akcie Aurinia Pharma online

Business Summary: Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Aurinia Pharmaceuticals Inc revenues increased 34% to $235.1M. Net income totaled $5.8M vs. loss of $78M. Revenues reflect US segment increase of 33% to $210.1M, Japan segment increase of 43% to $25M. Net Income reflects Therapeutic Drug Division segment loss decrease of 95% to $4.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.54 to $0.04.